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S282 Poster Session IIof SCT were 42% both in pts age\60(8/19) and in pts$ 60 (3/7).
In contrast to a report from another institute in which 14/99 pts
age $50 received SCT in CR, 7/16 in this current study did so
(p5 0.01). Rates of SCT were 6/13 in pts at highest risk based
on cytogenetics and FLT3 status and 3/11 in pts at lower (i.e. ‘‘in-
termediate’’ risk; risk status not known in 2) Three of the 15 pts
who did not receive SCT had available donors, but 12 were not
HLA -typed. Age distribution was similar (p5 0.31) in pts who
were and were not HLA-typed and in only 2 non-typed pts were
financial considerations or pt refusal an issue. Rather, notes sug-
gested that physicians felt that pts were doing well and might not
need SCT. We also examined our 21 consecutive pts who were un-
der age 70, did not receive SCT in CR1, and were given first sal-
vage therapy (S1) for relapse, again with at least 4 months
follow-up from relapse date. These 21 included patients referred
to us at initial diagnosis or only at time of S1. The frequency
with which they were transplanted (8/21; 38% 95% CI 18-62%)
did not differ from the frequency with which SCT was done in
CR1. However SCT was most commonly done as 2nd salvage ther-
apy (4 cases), with 3 pts transplanted in CR2 or CR and only 1
given SCT as S1. Ten of the 13 S1 pts never given SCT had avail-
able donors (3 related, 3 unrelated, 4 cord) and SCT was not done
because of high blasts and/or poor performance status. We con-
clude that although older and younger pts may be equally likely
to receive SCT in CR1, failure to HLA type may be a major im-
pediment to improving rates of SCT in CR1. Although relapsed
pts are transplanted as often as pts in CR1, such transplants are
only rarely used as initial therapy of relapse.334
HIGHER RATES OF FATAL BACTERIAL AND INVASIVE FUNGAL INFEC-
TIONS, BUT NO DIFFERENCE IN CYTOMEGALOVIRUS (CMV) REACTIVA-
TION SEEN WITH THE USE OF ALEMTUZUMAB IN A REDUCED
INTENSITY CONDITIONING REGIMEN
Shabbir, M., Costa, L., Fouts, T.V., Schaub, C., Kistner-Griffin, E.,
Maxwell, C., Rogers, K., Stuart, R.K. Medical University of South Caro-
lina, Charleston, SC
Background: Reduced intensity conditioning (RIC) for allogeneic
hematopoietic stem cell (HSC) transplantation is a well established
therapy for patients with advanced hematological malignancies.The
use of Alemtuzumab as part of RIC has been associated with decrease
in incidence and severity of graft versus host disease (GVHD), par-
ticularly in unrelated donor transplants.
Methods: This is a single center, prospective study. Patients who
were not candidates for full myeloablative conditioning regimens re-
ceived an non-Alemtuzumab (nA) containing RIC regimen or an
Alemtuzumab-containing regimen (A) based on the use of a matched
sibling or an unrelated donor, respectively. Patients in the nA group
were conditioned with either Fludarabine and total body irradiation
or Fludarabine and Melphalan. Patients in the A group received
Alemtuzumab,Fludarabine and Melphalan. All patients received tri-
methoprim/sulphamethoxazole for PCP prophylaxis, fluconazole for
fungal prophylaxis and acyclovir for viral prophylaxis. Treatment for
CMV reactivation was preemptively initiated with gancyclovir or
valgancyclovir when documented by positive CMV PCR in periph-
eral blood. Supportive care was standard across both groups.
Results: From January 2003 to March 2009, 56 patients were en-
rolled in the study and 50 patients went on to receive an HSCT
and are the subject of this analysis. Twenty nine patients were in-
cluded on group nA and 21 in group A. Median age of the patients
in the entire cohort was 55 years (range 14-65). Twenty four patients
in nA group and 16 patients in A group were considered high risk for
CMV reactivation post transplant because of donor and/or recipient
positive CMV serological status. Rates of CMV reactivation was
similar between the two groups (75% in nA and 67% in A,
P5 0.19). Two patients developed CMV pneumonitis, and one de-
veloped CMV colitis in the A group and were successfully treated
with foscarnet and cytogam. Day 100 mortality was similar between
the 2 groups (20.7% for nA vs 33.1% for A, P5 0.31). The cumula-
tive incidence of treatment related mortality was higher in group A
(P5 0.02) due to significantly higher incidence of fatal bacterial orfungal infections (52% vs.24%, p5 0.04), with most deaths occur-
ring beyond day 100.
Conclusion: Alemtuzumab is associated with increased transplant
related mortality due to overwhelming bacterial and fungal infec-
tions with no differences in rate of CMV reactivation or fatal
CMV disease.
Non-Alemtuzumab Alemtuzumab
REGIMEN Group (nA) group (A)No OF PATIENTS 29 21
AGE 55 (14-64) 60 (14-60)
DISEASE
AML 8 10
NHL 6 6
MDS 6 2
MM 2 1
CLL 3 0
CML 4 2
PREVIOUS TREATMENT
0-1 8 6
2-3 14 6
.3 7 9
RISK CATEGORY
Low/Intermediate risk 16 11
High risk 13 10Patient Charecteristics.335
COMPLEX KARYOTYPE PREDICTS POOR RESPONSE TO SALVAGE THER-
APY AND INELIGIBILITY FOR REDUCED INTENSITY CONDITIONING
TRANSPLANTATION IN CLL
Jaglowski, S.M.1, Heerema, N.2, Elder, P.1, Scholl, D.1, Hamadani, M.3,
Byrd, J.C.1, Devine, S.1, Andritsos, L.A.1 1The Ohio State University,
Columbus, OH; 2The Ohio State University, Columbus, OH; 3West Vir-
ginia University, Morgantown, WV
Introduction: Allogeneic stem cell transplantation (aSCT) is the
only potentially curative therapeutic option for patients with
CLL. In spite of recent improvements in transplant-related mortal-
ity due to the introduction of reduced-intensity conditioning
(RIC), only a small proportion of patients ultimately undergo
transplantation. An inability to attain a remission is one important
reason why patients are unable to receive a transplant. This study
evaluates metaphase and interphase cytogenetic abnormalities in
patients who were not able to undergo aSCT because of inability
to attain a remission.
Patients and Methods: All patients with CLL referred for a trans-
plant evaluation from January 2003 to the present were included in
this study. Two electronic databases, E-Results and TransChart,
were reviewed to determine which patients were transplanted, and
of those who were not, the reason for not proceeding to aSCT.
The chromosomal profiles of these patients were evaluated.
Results:The results are summarized in Table 1. From January 2003
to the present, 34 patients with CLL were transplanted at our insti-
tution, and 31 were ineligible for transplant because of inability to
attain disease control. The median number of prior treatments in
each group was 2, and the average ages of patients who were trans-
planted and those who were not were 55 and 56.6 years respectively.
Of the 34 patients who underwent transplantation, 12 had a complex
karyotype ($ 3 cytogenetic abnormalities on metaphase analysis) and
22 had 0-2 karyotypic abnormalities. This contrasts with patients
who could not attain remission: 19 had a complex karyotype and
12 did not (p5 0.03). When cytogenetic abnormalities were further
analyzed, there was no statistically significant influence of other high
risk cytogenetic abnormalities (del 17p13 17 or del 11q22.3) on abil-
ity to proceed to transplant.
Conclusions: Currently, the presence of the del 17p13 is the only
cytogenetic indication for transplant in first remission in patients
with CLL. These data indicate that a complex karyotype may be
an important factor in determining whether a patient will have a suf-
ficient response to salvage therapy to undergo subsequent aSCT.
Poster Session II S283The propensity towards clonal evolution may play a key role in de-
termining which patients should be evaluated for transplant earlier
in their disease course.
Summary of metaphase and interphase cytogenetic abnor-
malities
# Abnormalities Transplant No Remission p-value0 6 5
1 4 5
2 12 2
3 1 3
4 3 1
5 or more 8 15 0.03
Cytogenetics
trisomy 12 4 5
del13q 13 19
del11q 8 8
del17 p 14 17 0.197336
FASTER LYMPHOCYTE RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) PREDICTS FOR DECREASED NON-
RELAPSE MORTALITY (NRM) IN ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL)
Yuen, C.H., Saliba, R.M., Andersson, B.S., Shpall, E., Popat, U.R.,
Qazilbash, M.H., Hosing, C., de Lima, M.J., Giralt, S.A.,
Champlin, R.E., Kebriaei, P.M.D. Anderson Cancer Center, Houston, TX
Allogeneic HCT remains an effective means of long-term disease
control in adult ALL, but high NRM with HCT in these heavily pre-
treated patients (pts) limits overall survival (OS). We looked at pre-
dictors for NRM and OS in pts who had received allogeneic HCT
for intermediate or high risk ALL from 2005 through 2009 at MD
Anderson Cancer Center. 65 pts with median age 32 years (range
18-62) with ALL in remission (CR15 29, CR25 19, greater than
CR25 5) or relapse (n5 5) were identified. Pts received a matched
related (n5 37) or matched unrelated (n5 28) peripheral blood
(n5 50) or bone marrow (n5 15) T-cell replete transplant following
myeloablative conditioning (Busulfan130 mg/m24/Melpha-
lan70 mg/m22, n5 42; TBI12 Gy/Etoposide 60 mg/kg n5 23).
All patients received tacrolimus and mini-dose methotrexate for
GVHD prophylaxis; unrelated donors additionally received anti-
thymocyte globulin. OS and NRM rates at 2 years were 47% and
32%, respectively, with median follow-up after HCT of 18 months.
Age, disease stage at time of HCT, cytogenetic risk, donor type, cell
source, conditioning regimen, and absolute lymphocyte count on
day 21 (D21ALC) and day 30 (D30ALC) post HCT were evaluated
in a univariate analysis with regards to impact on NRM and OS using
the Cox proportional hazards model. All outcomes were estimated in
landmark analysis starting on day 21 or day 30 as indicated by ALC.
Age .45 years was associated with increased NRM and worse out-
come (HR 4.5, 95%CI 1.1-11.7, p5 0.002 for NRM; HR 2.3,
95% CI 1.1-4.9, p5 0.02 for OS). Early disease (CR1 or CR 2 vs ad-
vanced disease) was associated with decreased NRM and better out-
come (HR 0.4, 95% CI 0.1-0.9, p5 0.04 for NRM; HR 0.3, 95%CI
0.2-0.7, p5 0.003 for OS). Median D21ALC was 300/uL. D21ALC
.300/uL was associated with decreased NRM and better outcome
(HR 0.4, 95%CI 0.1-0.9, p5 0.035 for NRM; HR 0.6, 95%CI
0.3-1.2, p5 0.1 for OS). D30ALC greater than median level 650/
uL was not associated with better outcome. When analyzed by donor
type, faster ALC recovery was significantly associated with better
outcome in unrelated HCT vs related HCT (p5 .035 vs. p5 0.2).
Further, no association was noted between ALC recovery and disease
stage or age. Small sample size prohibited multivariate analysis. An
association between ALC recovery and HCT outcome has been pre-
viously reported for adult ALL, although this is the first report for
such an association following matched unrelated HCT. A larger
study is needed to confirm these findings.337
BUSULFAN-BASED REDUCED INTENSITY CONDITIONING REGIMEN (RIC)
FOR LYMPHOID MALIGNANCIES
Sekhar, J.1, Stockerl-Goldstein, K.1, Cashen, A.1, Zhang, Q.2,
Witowski, S.1, Abboud, C.1, Uy, G.1, Westervelt, P.1, Dipersio, J.1,
Vij, R.1 1Washington University School of Medicine, St. Louis, MO;
2Washington University School of Medicine, St Louis, MO
Introduction:Though busulfan (Bu) based RIC are popular for my-
eloid malignancies there is a paucity of data on Bu- based RIC for
lymphoid neoplasms. We therefore conducted a single institution
retrospective analysis of a large patient cohort allografted using:
Bu/Fludarabine (Flu) +/- Thymoglobulin (Thymo) RIC regimens
for lymphoid malignancy.
Methods: 62 patients (pts) underwent RIC for lymphoid malignan-
cies between 2004 and 2008 using Bu 0.8 mg/kg q6 hrs 8 doses d-4
d-3, Flu 30 mg/m2 IV d -7 to -3, +/- Thymo 2 mg/kg 4 d-4 to d-1.
Graft versus host disease (GVHD) prophylaxis was tacrolimus (FK)/
methotrexate(Mtx)/mycophenolate(MMF) in 41 pts (65%), FK/Mtx
in 20 pts (32%), cyclosporine/MTx/MMF in 2 pt (3%).
Demographics: Median age 53 (range 20-65) yrs; males 39 (63%)
females 23 (37%); CLL/SLL 21 (34%), non-Hodgkins lymphoma
32 (52%) Hodgkins lymphoma 9 (14%); therapies prior to transplant
4 (range 0-13); Bu/Flu17 pts (27%), Bu/Flu/Thymo 45 pts (73%);
prior radiation therapy (XRT) 45 pts (73%), prior autologous stem
cell transplant (ASCT) 27 pts (30%); median comorbidity index
score (CI) 1 (range 0-5).
Results: After median F/U of 14 mo (0.4-48), Kaplan-Meier esti-
mates of median overall survival (OS) and progression-free survival
(PFS) were 18.3 mo and 9.8 mo, respectively. 2-yr OS was 49.6%,
and the PFS was 47.7%. 100 day, 1 year, 2 year non-relapse mortality
(NRM) was 8%, 31%, and 35%, respectively. We performed univar-
iate (Table 1) and multivariate analyses for OS, PFS, and NRM. On
multivariate analysis, prior XRT, high CI score, and\PR post
transplant had adverse effects on OS (p5 0.0145, 0.002, 0.0065, re-
spectively); prior XRT and\PR post transplant adverse effects on
PFS (p5 0.0148, p\0.001); and high CI score adverse effects on
NRM (p5 0.0324).
Conclusion: This represents the largest single institution experi-
ence using Bu/Flu +/- Thymo in lymphoid malignancies. We dem-
onstrate prompt, durable engraftment and relatively low NRM.
Prior XRT, CI score, and transplant response predicted for OS;
prior XRT and transplant response for PFS; CI score for NRM.
Table 1. Univariate Analyses
OS-2 years p-value PFS-2 years p-valueAge
\55 56% 0.23 45% 0.74
./5 55 40% 37%Diagnosis
CLL/SLL 52% 0.57 52% 0.41
Non Hodgkins 46% 43%
Hodgkins 64% 13%# lines of chemotherapy
\4 62% 0.61 46% 0.25
./5 4 41% 38%Prior Auto
Yes 55% 0.13 53% 0.08
No 42% 25%Donor Type
Related 47% 0.65 32% 0.39
Unrelated 52% 49%Prior Radiation
Yes 62% 0.008 54% 0.003
No 31% 23%Response to Transplant
CR or PR 62% \0.0001 53% \0.0001
Stable or Prog Disease 20% 15%CI Score
Low 58% 0.01 48% 0.04
Intermediate 54% 45%
High 11% 11%
